Journal article
Effect of aspirin on disability-free survival in the healthy elderly
JJ McNeil, RL Woods, MR Nelson, CM Reid, B Kirpach, R Wolfe, E Storey, RC Shah, JE Lockery, AM Tonkin, AB Newman, JD Williamson, KL Margolis, ME Ernst, WP Abhayaratna, N Stocks, SM Fitzgerald, SG Orchard, RE Trevaks, LJ Beilin Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2018
Abstract
Background: Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disabilityfree life in healthy seniors is unclear. Methods: From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or physical disability. Participants were randomly assigned to receive 100 mg per day of enteric-coated aspirin or placebo orally. The primary end point was a composite of death, dementia, or persistent phys..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583.